Sensitivity of Medicare Claims to Identify Cancer Recurrence in Elderly Colorectal and Breast Cancer Patients
暂无分享,去创建一个
Angela Mariotto | Deborah Schrag | A. Mariotto | D. Penson | J. Warren | D. Schrag | K. Yabroff | K Robin Yabroff | Joan L Warren | Danielle Melbert | Paul Doria-Rose | David Penson | Paul Doria-Rose | Danielle L. Melbert | Joan L. Warren
[1] A. Mariotto,et al. Accuracy and completeness of diagnosis codes for cancer metastasis on Medicare claims. , 2013 .
[2] A. Merati,et al. Impact of surveillance on survival after laryngeal cancer in the medicare population , 2009, The Laryngoscope.
[3] Beth A Virnig,et al. Utility of the SEER-Medicare Data to Identify Chemotherapy Use , 2002, Medical care.
[4] T. Church,et al. Colorectal cancer deaths as determined by expert committee and from death certificate: a comparison. The Minnesota Study. , 1999, Journal of clinical epidemiology.
[5] M. Stolar,et al. Identification of metastatic cancer in claims data , 2012, Pharmacoepidemiology and drug safety.
[6] G. Cooper,et al. The utility of Medicare claims data for measuring cancer stage. , 1999, Medical care.
[7] Ewout W Steyerberg,et al. Provider case volume and outcomes following prostate brachytherapy. , 2009, The Journal of urology.
[8] M. Stokes,et al. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[9] R. Sandler,et al. Identifying Specific Chemotherapeutic Agents in Medicare Data: A Validation Study , 2013, Medical care.
[10] Kathleen Lang,et al. Identifying Cancer Relapse Using SEER-Medicare Data , 2002, Medical care.
[11] M. Symons,et al. Racial Differences in Clinical Progression Among Medicare Recipients After Treatment for Localized Prostate Cancer (United States) , 2006, Cancer Causes & Control.
[12] Nicholas A. Christakis,et al. Measuring Disease-Free Survival and Cancer Relapse Using Medicare Claims From CALGB Breast Cancer Trial Participants (Companion to 9344) , 2006, Journal of the National Cancer Institute.
[13] P. Marcus,et al. Death certificates provide an adequate source of cause of death information when evaluating lung cancer mortality: an example from the Mayo Lung Project. , 2009, Lung cancer.
[14] J. Weeks,et al. Use of stereotactic radiosurgery for brain metastases from non-small cell lung cancer in the United States. , 2013, International journal of radiation oncology, biology, physics.
[15] G. Cooper,et al. Use of SEER-Medicare Data for Measuring Cancer Surgery , 2002, Medical care.
[16] J. Goodwin,et al. Surveillance of Pancreatic Cancer Patients after Surgical Resection , 2012, Annals of Surgical Oncology.
[17] V. Bollu,et al. Epidemiology, survival, and costs of localized gastrointestinal stromal tumors , 2011, International journal of general medicine.
[18] P. Nelson,et al. Determining cause of death in prostate cancer: are death certificates valid? , 2001, Journal of the National Cancer Institute.
[19] Dejian Lai,et al. Hazard of Recurrence among Women after Primary Breast Cancer Treatment—A 10-Year Follow-up Using Data from SEER-Medicare , 2012, Cancer Epidemiology, Biomarkers & Prevention.
[20] Deborah Schrag,et al. Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population , 2002, Medical care.
[21] J L Freeman,et al. Accuracy and completeness of Medicare claims data for surgical treatment of breast cancer. , 2000, Medical care.
[22] Gregory S. Cooper,et al. Studying Radiation Therapy Using SEER-Medicare-Linked Data , 2002, Medical care.